Recommendation of the President – Embavi (apixaban)

On 24 March 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 38/2026 on the inclusion of the medicinal product Embavi (apixaban) in the reimbursement program for the indication: prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( Non-Valvular Atrial Fibrillation, NVAF) and at least one risk factor, such as: history of stroke or transient ischemic attack (TIA); age ≥ 75 years; hypertension; diabetes; symptomatic heart failure (NYHA class ≥II)

Publication in Public Information Bulletin (BIP) >>